PATENT CLAIM ANALYSIS

Application Number: 16179050
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["540", "555000"]

Abstract:
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C  receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C  receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C  receptor.

Claim (Index 51):
A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as claimed in any of the preceding claims or an N-oxide, a tautomeric form, a stereoisomer or a pharmaceutically acceptable salt thereof, or comprising at least one compound as defined in any of the preceding claims wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope, preferably wherein at least one hydrogen atom has been replaced by a deuterium atom, in combination with at least one pharmaceutically acceptable carrier and/or auxiliary substance.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.88636
- Patent Class: 540.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13838788', '14657840', '14657916', '14026354', '14868835']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7065027371477131
- 35 USC 102 Novelty (BERT): 0.6137325785347852
- Combined Prediction Score: 0.6972257212864204
- Mean Citation Score: 483.115398
- Max Citation Score: 558.0024
- Similarity Product: 479.99675085840215

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test